Medical Economics January 22, 2024
Denise Myshko

FDA gave nod to six vaccines in 2023, including RSV for infants and older adults

Last year saw the approval of several firsts in vaccine approvals, including the first vaccines to prevent respiratory syncytial virus (RSV) in older adults and infants and a first vaccine to prevent the mosquito-borne virus chikungunya.

Vaccinations are among the most important public health tools for preventing serious illness, avoiding hospitalizations and saving lives. During the COVID-19 pandemic, vaccine technology made a huge leap forward with the introduction of messenger RNA (mRNA) vaccines. COVID-19 vaccines developed by BioNTech/Pfizer and Moderna use mRNA instead of weakened viruses or virus fragments to teach the body’s immune system how to respond when presented with an infection.

Innovation in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Common Trends in GLP-1 Use Amid Increased Indications
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more

Share This Article